News Releases

Month Year

Month Year

Investor Alerts

Apr 23, 2023

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma
Apr 19, 2023

IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
Apr 3, 2023

IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
Mar 31, 2023

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 14, 2023

IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase
Mar 7, 2023

IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
Mar 1, 2023

IDEAYA Biosciences to Participate in Investor Conferences in March 2023
Feb 16, 2023

IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit
Feb 1, 2023

IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
Jan 23, 2023

IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

Show per page